A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
Financial Summary
| Share Statistics | NCEL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $19.4 | $282.4 | 10% |
|
| Shares Out (Mil) | 3.4 | 54.0 | 11% |
|
| Institutional Ownership | 0.9% | 93.1% | 2% |
|
| Float (Mil) | 2.7 | 42.2 | 7% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 10 | 482 | 17% |
|
| Price Change (52-week) |
na | 59.9% | na |
|
| Growth | NCEL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (4.1%) | (10.1%) | 35% |
|
| EPS (5yr) | 14.0% | 15.9% | 54 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (35.7%) | (15.6%) | 14% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NCEL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($8) | ($43) | 30% |
|
| EPS (TTM) | ($2.159) | ($1.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($31) | 28% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $18 | $190 | 10% |
|
| Valuation | NCEL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.22 | 2.84 | 54% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | NCEL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (134.4%) | (47.7%) | 4% |
|
| ROE | na | (55.0%) | na |
|
| Liabilities to Assets | 36.7% | 29.8% | 28% |
|
| F-Score | 3 | 3 | 18% |
|
NewcelX Ltd. did not pass any screens on 9/4/2026.
